Ascendis Pharma A/S (NASDAQ:ASND) Given New $341.00 Price Target at Barclays
by Renee Jackson · The Cerbat GemAscendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target raised by research analysts at Barclays from $329.00 to $341.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price would suggest a potential upside of 24.19% from the company’s current price.
ASND has been the topic of several other research reports. BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. HC Wainwright reduced their target price on Ascendis Pharma A/S from $344.00 to $335.00 and set a “buy” rating for the company in a research note on Friday. UBS Group lifted their target price on Ascendis Pharma A/S from $269.00 to $315.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen boosted their target price on Ascendis Pharma A/S from $341.00 to $352.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Sunday, November 8th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $314.10.
Read Our Latest Stock Analysis on ASND
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND traded down $0.81 during mid-day trading on Monday, hitting $274.58. The stock had a trading volume of 58,985 shares, compared to its average volume of 700,582. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.29 and a current ratio of 2.89. The stock has a market cap of $17.13 billion, a price-to-earnings ratio of 17.97 and a beta of 0.40. The company’s 50 day simple moving average is $242.67 and its 200 day simple moving average is $239.83.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.47% and a net margin of 73.26%. On average, equities research analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.
Insider Activity at Ascendis Pharma A/S
In related news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 40.00% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after acquiring an additional 450,000 shares during the period. Sei Investments Co. increased its stake in shares of Ascendis Pharma A/S by 24.8% during the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after purchasing an additional 69,673 shares during the period. Frazier Life Sciences Management L.P. increased its stake in shares of Ascendis Pharma A/S by 68.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after purchasing an additional 91,822 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Ascendis Pharma A/S by 27.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock worth $51,602,000 after purchasing an additional 48,275 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Ascendis Pharma A/S by 0.5% during the third quarter. Empowered Funds LLC now owns 188,229 shares of the biotechnology company’s stock worth $42,884,000 after purchasing an additional 958 shares during the period.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Recommended Stories
- Five stocks we like better than Ascendis Pharma A/S
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?